SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode

 
• By Alaric DeArment

The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.

While SpringWorks is initially pursuing desmoid tumors, multiple myeloma represents a much bigger market • Source: Shutterstock

More from Anticancer

More from Therapy Areas